DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain.
Cristóbal Morales-PortilloVirginia BellidoCristina TejeraFernando GoñiRafael PalomaresCristina SevillanoDiego BellidoAlfonso SotoMiguel Ángel MangasManuel A BotanaIrene CaballeroPublished in: Journal of comparative effectiveness research (2021)
Background: Weight reduction and glycemic control are key goals during Type 2 diabetes management. However, there are few country-specific, real-world data on cotransporter 2 inhibitors. Materials & methods: DAPA-RWE was a retrospective, multicenter study comparing the efficacy of dapagliflozin versus sitagliptin in Type 2 diabetes patients in Spain. Results: The study population comprised 1046 patients (594 with dapagliflozin, 452 with sitagliptin). Age was 61.8 ± 10.0 and 66.2 ± 11.4 years and glycosylated hemoglobin (HbA1c) 8.9 and 8.8%, respectively. The main end point (reduction in weight and HbA1c) was reached by 24.4 and 56.1% of patients, respectively; p < 0.05. This was confirmed with a propensity score matching analysis balanced for obesity-related variables at baseline. Conclusion: DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.
Keyphrases
- type diabetes
- glycemic control
- weight loss
- end stage renal disease
- clinical practice
- newly diagnosed
- ejection fraction
- body mass index
- insulin resistance
- chronic kidney disease
- weight gain
- physical activity
- peritoneal dialysis
- cardiovascular disease
- prognostic factors
- metabolic syndrome
- public health
- electronic health record